Results 151 to 160 of about 22,609,350 (346)
The cytoplasmic tail of CTLA-4 is dispensable for Nef-induced CTLA-4 down-regulation.
a) Accumulation of CTLA-4 on the cell surface after transfection with CTLA-4 Y201AY218G and CTLA-4ΔCT mutants and lower expression after transfection with CTLA-4 LL181AA. Black solid histograms represent the isotype controls.
Rabih Halwani (287270) +14 more
core +1 more source
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang +4 more
wiley +1 more source
Alveolar echinococcosis (AE) is a zoonotic parasitic disease caused by the infection of Echinococcus multilocularis (E. multilocularis) larvae. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) produces inhibitory signals and induces T cell exhaustion, thereby ...
Yuxuan Yang +8 more
doaj +1 more source
Viewpoint: Therapeutic Implications of CTLA-4 Compartmentalization
Understanding the regulatory events involved in the activation and inactivation of T cells is crucial to develop therapeutic approaches for autoimmune diseases and for organ transplantation. Co-stimulatory signals delivered through the CD28 receptor and inhibitory signals through CTLA-4 are required for the proper modulation of T cell responses and the
Baroja, Miren L., Madrenas, JoaquÃn
openaire +4 more sources
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Background: CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.
Nithya Krishnamurthy +9 more
doaj +1 more source
We developed a dissolvable microneedle patch that locally delivers a radiolabeled coordination polymer designed to simultaneously destroy tumor cells and stimulate antitumor immunity through STING activation and pyroptosis. This strategy significantly inhibited melanoma growth and improved the effectiveness of immune checkpoint therapy, highlighting a ...
Pian Yu +12 more
wiley +1 more source
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Scott J Rodig +17 more
semanticscholar +1 more source
Degradation of CTLA-4 chimeras.
A. CHO cells expressing CTLA-4 chimeras were incubated in medium or medium supplemented with cycloheximide (CHX) at 37°C for 3 hours. Cells were fixed, permeabilised and stained for total CTLA-4 with an unlabeled anti-CTLA-4 Ab followed by Alexa488 anti ...
Satdip Kaur (397530) +2 more
core +1 more source

